Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Blincyto
(United States) [Available]Synonyms :
blinatumomab
Class :
Antineoplastic agents and monoclonal antibodies
Brand Name :
Blincyto
(United States) [Available]Synonyms :
blinatumomab
Class :
Antineoplastic agents and monoclonal antibodies
Dosage Forms & Strengths Â
Solution Â
35 mcg/vial Â
38.5 mcg/vial  Â
Acute Lymphoblastic Leukemia(All)
For >45 kg: Administer a dose of 28 mcg intravenous route one time daily with continuous infusion on the day 1 to day 28 up to 6-week cycle including total 4 cycles
For <45 kg: Administer a dose of 15 mcg/m2 intravenously one time daily with continuous infusion on the day 1 to day 28 up to 6-week cycle including total 4 cycles
Dosage Forms & Strengths Â
Solution Â
35 mcg/vial Â
38.5 mcg/vial  Â
Acute Lymphoblastic Leukemia(All)
For <45 kg:
Administer a dose of 15 mcg/m2 intravenous route one time daily with continuous infusion on the day 1 to day 28 of a 6-week cycle including total of 4 cycles
Refer to adult dosingÂ
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
it may reduce the therapeutic efficacy of the vaccine
it may increase the bone marrow suppression effect of cladribine
it may reduce the therapeutic efficacy of the vaccine
it may reduce the therapeutic efficacy of the dengue vaccine
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
it may increase the bone marrow suppression effect of dipyrone
it may reduce the therapeutic effect of Fc-receptor binding agents
it may increase the bone marrow suppression effects of fexinidazole
it may reduce the therapeutic effects of the vaccine
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in adverse/toxic effects of bone marrow suppression and neutropenic effect
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
it may enhance the serum concentration of busulfan
when both drugs are combined, there may be an increase in adverse/toxic effects of bone marrow suppression
it may increase the bone marrow suppression effect of clozapine
when both drugs are combined, there may be an increase in adverse/toxic effects of bone marrow suppression and neutropenic effect
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in adverse/toxic effects of bone marrow suppression and neutropenic effect
it may increase the bone marrow suppression effects of promazine
when both drugs are combined, there may be an increase in adverse/toxic effects of immunosuppression and the risk of severe infection
when both drugs are combined, there may be an increase in adverse/toxic effects of immunosuppression and the risk of severe infection
it may enhance the adverse effects when combined with aducanumab
The potential for bleeding risk or its seriousness may elevate when blinatumomab is used together with troxerutin
When mometasone furoate is used together with blinatumomab, this leads to enhanced risk or seriousness of adverse outcomes
When blinatumomab is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
blinatumomab: it may increase the risk of bleeding with trapidil
technetium Tc-99m arcitumomabÂ
the risk or extent of adverse effects can be raised when technetium tc-99m arcitumomab is combined with blinatumomab
Action and spectrum:Â
Blinatumomab binds to CD3 which is expressed at T cell surfaces and CD19 which is expressed at the surface of B-lineage cells.Â
Frequency defined:Â Â
>10%Â
Cardiac arrhythmia Â
Weight gain  Â
Anemia  Â
NeutropeniaÂ
Skin rash Â
Increased serum transaminases Â
Headache Â
Back pain Â
Tremor Â
Fever  Â
1-10%Â Â
Seizure Â
EncephalopathyÂ
DizzinessÂ
Febrile neutropenia  Â
Frequency not defined:Â Â
Allergic dermatitis Â
Erythema Â
Urticaria Â
 Black Box Warning  Â
None Â
Contraindication/Caution:Â Â
Contraindication:Â Â
HypersensitivityÂ
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation:Â
Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â Â
Blinatumomab is indicated to treat acute lymphoblastic leukemia (ALL). Â
ALL is a blood cancer with one type of white blood cell growing out of control.Â
Pharmacodynamics:Â Â
Blinatumomab encourages to promote peripheral redistribution of T-cells after initiation of infusion.  Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
It is administered as continuous intravenous infusion.Â
Generic Name: blinatumomabÂ
Pronuncition: blih-nuh-TOO-moh-mabÂ
Why do we use blinatumomab? Â
Blinatumomab is an immunotherapy known as a bispecific T-cell engager (BiTE). It works by linking healthy T cells to leukemia cells, allowing the T cells to better attack the cancer. It targets CD3 on T cells and CD19 on cancerous B cells found in acute lymphoblastic leukemia.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
